Saltar al contenido principal
Pan y Hierro Nutrition and exercise with sources

Blog

Omega-3: what Cochrane says and why fish is still worth keeping

What 86 trials with 162,796 people show about omega 3 and cardiovascular disease, and why the advice is still to eat fish.

There are two recommendations that in nutrition leaflets are almost never seen together and that nevertheless contradict each other: “eat fish” and “omega 3 supplements add nothing”. Both have documentary support, and they come from sources of a different nature.

What the trials say

The Cochrane review on omega 3 and cardiovascular disease is the most cited and most debated document in the field. The current version is the 2020 one, which replaces the 2004 version and greatly widens the scope: 86 randomized trials with 162,796 participants, of which 28 are at low risk of bias, with a search updated to February 2019 [1].

The main results distinguish the two families of omega 3. For the long-chain ones, EPA and DHA [1]:

  • All-cause mortality: no reduction demonstrated, high certainty [1].
  • Cardiovascular events: likewise no reduction demonstrated, high certainty [1].
  • Cardiovascular mortality: around 8 % less, with moderate certainty [1].
  • Coronary events: around 9 % less, with low certainty. Coronary mortality sat on the threshold, without being demonstrated, also with low certainty [1]. The last two are the estimates that come closest to a benefit, and the ones with the lowest certainty. The review turns them into a number that helps to gauge it: 167 people treated with EPA and DHA for 12-88 months for each coronary event avoided, and 334 for each coronary death avoided [1].

The effect did not vary with the duration of the trial or with the omega 3 dose. The result that is solid: EPA and DHA reduce triglycerides by around 15 %, with no effect on other lipids or on body weight, with high certainty [1].

For alpha-linolenic acid (ALA) of plant origin, the meta-analysis is much smaller and its effect on mortality is also nearly nil: it is associated neither with all-cause mortality nor with coronary events, with moderate or low certainty [1].

Two more caveats: the evidence on eating fish as such is scarce, because most trials used capsules, and the trials lasted between 12 and 88 months [1].

What it means in practice

The review’s conclusion, in its own terms: the moderate- and low-certainty evidence suggests that increasing long-chain omega 3 slightly reduces the risk of death from coronary heart disease and of coronary events, and that increasing ALA slightly reduces the risk of cardiovascular events and of arrhythmias [1].

The expected benefit in all-cause mortality and in cardiovascular events could not be demonstrated with high certainty, and the benefits that were found are small and of low certainty. It also found no increase in cardiovascular events or in other adverse outcomes [1]. An effect not being demonstrated is not the same as the effect not existing.

The nuance about cancer

Earlier Cochrane reviews warned that, although there were no signs of an increased cancer risk, the estimates were too imprecise to rule out a clinically meaningful effect. The 2020 version focuses on cardiovascular outcomes and does not carry that cancer assessment forward [1].

The lesson still holds: “we saw no sign of harm” is not the same as “we have ruled out harm”.

Where omega 3 comes from in the diet

The WHO healthy diet fact sheet lists fish among the sources of unsaturated fat, along with avocado, nuts and sunflower, soybean, rapeseed and olive oils [2]. And it is consistent with the rest of its advice: less saturated fat (fatty meats, butter, palm and coconut oil, cream, cheese, ghee and lard) and less industrial trans fat [2].

The IOM, for its part, separates two families that should not be mixed [3]:

  • Alpha-linolenic acid (ALA), of plant origin, which is the omega 3 that dominates the Western diet.
  • EPA and DHA, of marine origin, which are the ones at the center of the clinical debate.

That difference matters: a good part of the trials measured fish oil with EPA and DHA, whereas the recommendation rests on a broader set of foods.

And legumes, which also count

A note on the other half of the pattern: the evidence on legumes and cardiometabolic health found a prospective inverse association with cardiovascular and coronary disease, with no significant association for type 2 diabetes or stroke [4]. Legumes are a source of plant protein, fiber and minerals, and they are part of the pattern the WHO recommends [2].

Dosage: there is no reliable reference value

The available sources treat omega 3 within the set of fatty acids and total fats [3], not as an isolated amount. There is no reliable reference value for omega 3 intake, so this page does not publish a dosage figure. The amount does show up on the label: look at the grams of fatty fish.

In summary

  1. Cochrane reviewed 86 trials and 162,796 participants and found no reduction in all-cause mortality or in cardiovascular events, both with high certainty [1].
  2. There is a small, low-certainty reduction in coronary events and coronary death: on the order of 9 % [1].
  3. The effect that is solid and measurable is the reduction of triglycerides by around 15 % with EPA and DHA [1].
  4. Public health advice is still to eat fish, because of the pattern as a whole, not because of a supplement [2].

If you have already been diagnosed with coronary heart disease and you take anticoagulants or supplements, the decision about omega 3 is your doctor’s, not this page’s.

More in: the supplements page, with the figures and the sources of the Nutrition section.

Related articles

Sources for this article (4) 4 references
  1. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KHO, Summerbell CD, Worthington HV, Song F, Hooper L (2020) Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD003177. (pub5; revisión actual que sustituye a la de 2004). See source (opens in a new tab) DOI: 10.1002/14651858.CD003177.pub5 Revisión Cochrane actual (86 ensayos, 162.796 participantes) sobre ácidos grasos omega 3 y enfermedad cardiovascular Licence: Resumen y hoja de resultados de la Cochrane Library. Se cita con enlace; no se reproduce texto salvo cita breve verificable. Consulted:
  2. Organización Mundial de la Salud (OMS) (2026) Healthy diet — hoja de datos. Organización Mundial de la Salud (OMS). See source (opens in a new tab) Hoja de datos de la OMS (recomendaciones de salud pública) Licence: OMS: el contenido de esta web está disponible bajo licencia CC BY-NC-SA 3.0 IGO. Se cita con enlace. Consulted:
  3. Institute of Medicine (IOM, National Academies) (2005) Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The National Academies Press, Washington, DC. See source (opens in a new tab) Informe de consenso del Institute of Medicine (DRI de macronutrientes y fibra) Licence: Obra del Gobierno de los Estados Unidos (dominio público). Descarga gratuita en nap.edu. Consulted:
  4. Becerra-Tomás N, Papandreou C, Salas-Salvadó J, Bulló M, Viñas B, Estruch R, et al. (2019) Legume Consumption and Cardiometabolic Health. Advances in Nutrition 10(6). See source (opens in a new tab) DOI: 10.1093/advances/nmz003 Revisión narrativa con metaanálisis (consumo de legumbres y salud cardiometabólica) Licence: Artículo de revista disponible en PubMed Central, con derechos de autor (sin licencia libre). Se cita con enlace; no se reproduce texto salvo cita breve verificable. Consulted:

How to cite

Pan y Hierro (2026). Omega-3: what Cochrane says and why fish is still worth keeping. https://panyhierro.com/en/blog/omega-3-what-cochrane-says/. Updated October 3, 2026.